Westbrook JA, et al. - Experts sought to identify such DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer and to evaluate its utility in predicting response to adjuvant zoledronic acid. Findings did not suggest an association of high DOCK4 expression with metastasis to non-skeletal sites when these were assessed collectively. Conclusively, they noted a significant association of high DOCK4 in early breast cancer with aggressive disease and with future bone metastasis and is a potentially useful biomarker for subsequent bone metastasis risk.